Why Did Ken Griffin Buy Sweetgreen Stock?
In Q1, Ken Griffin’s Citadel Advisors purchased nearly 1.3 million…
Buy
75
DOCS Quote, Financials, Valuation and Earnings
Last price:
$56.31
Seasonality move
:
-1.14%
Day range:
$57.46 - $59.08
52-week range:
$25.00 - $85.21
Dividend yield:
0%
P/E ratio:
51.77x
P/S ratio:
20.27x
P/B ratio:
9.97x
Volume:
2M
Avg. volume:
3M
1-year change:
92.4%
Market cap:
$10.8B
Revenue:
$570.4M
EPS (TTM):
$1.11
Analysts' Opinion
-
Consensus RatingDoximity has received a consensus rating of Hold. The company's average rating is a Hold based on 5 Buy ratings, 11 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $61.94, Doximity has an estimated upside of 7.79% from its current price of $57.47.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $50.00 representing 100% downside risk from its current price of $57.47.
Fair Value
-
According to the consensus of 16 analysts, Doximity has 7.79% upside to fair value with a price target of $61.94 per share.
DOCS vs. S&P 500
-
Over the past 5 trading days, Doximity has overperformed the S&P 500 by 4.93% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Doximity does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Doximity has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Doximity reported revenues of $138.3M.
Earnings Growth
-
Doximity has grown year-over-year earnings for 8 quarters straight. In the most recent quarter Doximity reported earnings per share of $0.31.
Enterprise value:
9.9B
EV / Invested capital:
9.12x
Price / LTM sales:
20.27x
EV / EBIT:
42.93x
EV / Revenue:
17.32x
PEG ratio (5yr expected):
0.96x
EV / Free cash flow:
37.04x
Price / Operating cash flow:
43.35x
Enterprise value / EBITDA:
41.03x
Gross Profit (TTM):
$514.5M
Return On Assets:
19.55%
Net Income Margin (TTM):
39.13%
Return On Equity:
22.82%
Return On Invested Capital:
22.82%
Operating Margin:
35.2%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $419.1M | $475.4M | $570.4M | $118.1M | $138.3M | |
| Gross Profit | $365.6M | $424.8M | $514.5M | $105.5M | $123.8M | |
| Operating Income | $125.1M | $171.8M | $230.1M | $41.9M | $48.7M | |
| EBITDA | $135.4M | $182.1M | $240.8M | $44.4M | $51.5M | |
| Diluted EPS | $0.52 | $0.72 | $1.11 | $0.20 | $0.31 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $209.4M | $904.1M | $975.5M | $912.9M | $1.1B | |
| Total Assets | $251.7M | $991.4M | $1.1B | $1.1B | $1.3B | |
| Current Liabilities | $102M | $111.3M | $139.5M | $147.3M | $156.3M | |
| Total Liabilities | $185M | $112.8M | $170.8M | $178M | $181.7M | |
| Total Equity | $66.7M | $878.6M | $966.1M | $901.4M | $1.1B | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $179.6M | $184.1M | $273.3M | $63.9M | $98.5M | |
| Cash From Investing | -$59.9M | $31.2M | -$29.3M | -$76.2M | -$24.5M | |
| Cash From Financing | -$74.5M | -$276.5M | -$131.1M | -$14.1M | -$29.7M | |
| Free Cash Flow | $173.4M | $178.3M | $266.7M | $62.3M | $97M | |
DOCS
Sector
Market Cap
$10.8B
$33.4M
Price % of 52-Week High
67.45%
47.1%
Dividend Yield
0%
0%
Shareholder Yield
1.1%
-0.6%
1-Year Price Total Return
92.4%
-36.6%
Beta (5-Year)
--
0.632
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$56.23
200-day SMA
Buy
Level
$53.43
Bollinger Bands (100)
Sell
Level
52.51 - 67.75
Chaikin Money Flow
Buy
Level
62.5M
20-day SMA
Buy
Level
$54.40
Relative Strength Index (RSI14)
Buy
Level
56.00
ADX Line
Buy
Level
20.05
Williams %R
Neutral
Level
-21.4511
50-day SMA
Buy
Level
$55.16
MACD (12, 26)
Buy
Level
0.36
25-day Aroon Oscillator
Sell
Level
-16
On Balance Volume
Neutral
Level
23.2M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (38.3398)
Buy
CA Score
(Annual)
Level (2.2019)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Buy
Ohlson Score
Level (-6.0144)
Buy
Piotroski F Score
(Annual)
Level (8)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (9)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Doximity Inc is a digital platform for U.S. medical professionals. The cloud-based platform provides members with tools specifically built for medical professionals, enabling them to collaborate with their colleagues, securely coordinate patient care, conduct virtual patient visits, stay up-to-date with the latest medical news and research, and manage their careers and on-call schedules.
Stock Forecast FAQ
In the current month, DOCS has received 5 Buy ratings 11 Hold ratings, and 0 Sell ratings. The DOCS average analyst price target in the past 3 months is $61.94.
-
Where Will Doximity Stock Be In 1 Year?
According to analysts, the consensus estimate is that Doximity share price will rise to $61.94 per share over the next 12 months.
-
What Do Analysts Say About Doximity?
Analysts are divided on their view about Doximity share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Doximity is a Sell and believe this share price will drop from its current level to $50.00.
-
What Is Doximity's Price Target?
The price target for Doximity over the next 1-year time period is forecast to be $61.94 according to 16 Wall Street analysts, 5 of them rate the stock a Buy, 0 rate the stock a Sell, and 11 analysts rate the stock a Hold.
-
Is DOCS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Doximity is a Hold. 11 of 16 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of DOCS?
You can purchase shares of Doximity via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Doximity shares.
-
What Is The Doximity Share Price Today?
Doximity was last trading at $56.31 per share. This represents the most recent stock quote for Doximity. Yesterday, Doximity closed at $57.47 per share.
-
How To Buy Doximity Stock Online?
In order to purchase Doximity stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will Planet Labs’ Stock Go Next?
On 4 June 2025 Planet reported Q1 FY 2026 revenue of $66.3 million, up 10% year over…
Where Will VICI Properties Be in 5 Years?
VICI Properties (NYSE:VICI) is a real estate investment trust focused…
Stock Ideas
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 40x
Buy
61
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 49x
Sell
39
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Buy
73
OKLO alert for Jun 12
Oklo [OKLO] is up 0.37% over the past day.
Buy
87
SMR alert for Jun 12
NuScale Power [SMR] is up 1.49% over the past day.
Buy
53
PLAY alert for Jun 12
Dave & Buster's Entertainment [PLAY] is up 0.72% over the past day.
